Skip to main content

Table 2 MoCA meetings and participation (09/2013 – 12/2022)

From: Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years’ multi-stakeholder dialogue on improving access in Europe via MoCA

Total number of meetings

47

Meetings per developer

Average: 2.9/ Median: 2/ Maximum: 9

Meetings per OMP

Average: 2.04/ Maximum: 6

Number of OMP developers participating /consortia

16

Number of OMPs discussed

23

Number of patients representatives

20

Number of payer-representing institutions that attended at least 1 meeting

27

Other participating institutions: Academia, as well as EMA and EUnetHTA as observers